This year, the FDA approved aprocitentan (TRYVIO™), a first-in-class dual endothelin A/endothelin B (ETA/ETB) receptor antagonist for the treatment of resistant hypertension.

Curious about the synthetic route of aprocitentan? Its synthesis combines key intermediates such as 5-(4-bromophenyl)-4,6-dichloropyrimidine and 2-[(5-bromopyrimidin-2-yl)oxy]ethan-1-ol. We offer our high-quality building blocks that include analogs of these compounds, designed to enhance your synthetic route efficiency.

In clinical trials, aprocitentan demonstrated sustained blood pressure reduction within 14 days and enhanced the effects of other antihypertensive agents, like RAS blockers. Altogether, its properties – including potential reductions in renal vascular resistance and left ventricular hypertrophy – underscore aprocitentan's value and the need for further large-scale clinical trials.

Discover our building blocks' potential, and let us support your team in synthesizing and studying the next generation of cardiovascular therapies. For orders and inquiries, contact us at sales@chem-space.com.